Clik here to view.
First Patient Recruited in Malignant Pleural Mesothelioma PhaseIb/II Trial
Scandinavian-based Targovax recently recruited the first patient for the Phase Ib/II study examining ONCOS-102 in combination with pemetrexed and cisplatin for the treatment of malignant pleural...
View ArticleClik here to view.
Positive Preclinical Results Reported in Mesothelioma Model for ONCOS-102
Results from a preclinical study using a mesothelioma animal model demonstrate a synergic effect of ONCOS-102, a genetically modified adenovirus, in combination with pemetrexed and cisplatin. “These...
View ArticleClik here to view.
Targovax Reports Promising Early Data on Vaccine Now in Mesothelioma Clinical...
Targovax recently presented preclinical and clinical results of the anti-tumor efficacy of its cancer vaccine ONCOS-102 for the treatment of malignant mesothelioma. The presentation, “OR52: Anti-tumor...
View ArticleClik here to view.
Targovax Granted European Patent for Vaccine to Treat Mesothelioma, Now in...
Targovax has been granted a European patent for its lead product ONCOS-102, a cancer vaccine that is being clinically evaluated in mesothelioma, with tests planned for other solid tumors. The...
View Article
